Pfizer Halts Development of Obesity and Diabetes Pill Due to Safety Concerns

Pfizer has ceased development of its experimental obesity and diabetes pill, lotiglipron, and will focus on its other oral obesity drug, danuglipron, which has shown promising results in phase two clinical trials. Plans for phase three trials are expected by the end of 2023.